ArticleFrontiers in nutrition2026
Circulating fatty acids and risk of gastrointestinal cancer in the UK Biobank.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Gastrointestinal(GI) cancer poses a significant threat to human health and safety, with studies suggesting a potential correlation between fatty acids(FAs) and GI diseases. We aim to comprehensively explore the association between plasma FAs and the risk of GI cancer and assess the causal effect of FAs on GI cancer risk through Mendelian randomization (MR). Methods: This prospective cohort study includes 230,415 cancer-free participants from the UK Biobank. We utilized Cox regression, restricted cubic splines, and accelerated failure time models to analyze the correlation between 17 circulating FAs and the risk of the overall GI cancer and five site-specific GI cancers, including esophageal cancer, stomach cancer, colorectal cancer, liver cancer and pancreatic cancer. And two-sample MR was employed to explore causal effects. Results: Over an average follow-up of 12.0 years, a total of 4,682 GI cancer cases were recorded. 14 FAs were found to be associated with GI cancer risk, with eleven exhibiting inhibitory effects, particularly significant in esophageal and liver cancers. MR results indicated causal associations between DHA/FA, SFA/FA, LA/FA, PUFA, and GI cancer risk. Conclusion: Circulating FAs are closely associated with GI cancer risk, aiding in the screening of high-risk populations. Moreover, targeted control of FAs levels may help reduce the risk of GI cancer occurrence in populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.